Develops targeted therapies for patients with genetically-defined cancers, focusing on mTOR pathway inhibitors.
Symbol: | AADI |
---|---|
Quote: | 2.05 |
Change: | -0.05 |
Change %: | -2.38% |
High: | 2.19 |
Low: | 2.02 |
Open: | 2.15 |
---|---|
Volume: | 62,607 |
52 Week: | 1.21-3.81 |
P/E Ratio: | -0.87 |
EPS: | -2.36 |
Market Cap: | 94.89 M |
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing precision therapies for genetically defined cancers characterized by alterations in mTOR pathway genes. Founded in 2007 and based in Pacific Palisades, California, Aadi focuses on developing and bringing to market innovative treatments that target specific genomic profiles associated with mTOR pathway activation. Their primary drug candidate, FYARRO, utilizes a formulation of sirolimus bound to albumin, currently undergoing evaluation across various cancer types with known mTOR pathway abnormalities.
FYARRO, Aadi Bioscience's lead therapeutic candidate, represents a novel approach in oncology by leveraging the synergistic potential of sirolimus and albumin in its formulation. The drug is being studied not only in tumor types traditionally associated with mTOR pathway activation but also in tumor-agnostic indications, aiming to address specific genetic alterations linked to mTOR pathway dysregulation. This strategic focus underscores Aadi's commitment to personalized medicine and its pursuit of therapies tailored to the molecular characteristics of individual patients.
With a robust pipeline and a foundation built on extensive research and development expertise, Aadi Bioscience continues to push the boundaries of canccer treatment innovation. By harnessing the therapeutic potential of mTOR pathway modulation, the company aims to deliver meaningful clinical benefits to patients while advancing the understanding and management of genetically defined cancers.
Exchange: | NASDAQ |
---|---|
Beta: | 0.339 |
Industry: | Biotechnology |
Sector: | Healthcare |
Employees: | 53 |
IPO Date: | Feb 16, 2018 |
![]() New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasdaq under the symbol "WHWK" effective March 19, 2025 Company... 1 months ago |
![]() MORRISTOWN, N.J. , March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. 1 months ago |
![]() Aadi Bioscience (AADI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 2 months ago |
![]() MORRISTOWN, N.J. , March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement. 2 months ago |
![]() MORRISTOWN, N.J. , March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting... 2 months ago |